Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.
Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.
This post was originally published on this site
Categories:
Business Day, Guardian, Health, Latest, Premium Times, Rheumatoid Drug Baricitinib, Uncategorized
